Magnetic resonance guided high intensity focused ultrasound ( MR ‐ HIFU ) effectively reduces fibroid‐related symptoms and improves quality of life—A prospective single‐centre 12‐month follow‐up study
Acta Obstetricia et Gynecologica Scandinavica · 2025-06 · 104 (6) · 1172-1180
DOI: 10.1111/aogs.15086 ↗At a glance
Klinische Studie (Phase IV) in Acta Obstetricia et Gynecologica Scandinavica, published online on 2025-04-29. Written by Saara Otonkoski and 7 co-authors. Institution: Department of Obstetrics and Gynaecology, Turku University Hospital, Turku, Finland. Major MEDLINE topics: High-Intensity Focused Ultrasound Ablation, Leiomyoma, Quality of Life, Uterine Neoplasms. Cited 8 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Finnish Government Research Funding.
Abstract (original language)
Introduction
Uterine fibroids are the most common benign tumors among women, and it is estimated that approximately 70% of women have one or multiple fibroids by the age of menopause. About 30% of these women suffer from symptoms related to the fibroids. Magnetic resonance‐guided high‐intensity focused ultrasound (MR‐HIFU) is a novel, non‐invasive treatment method for symptomatic uterine fibroids. Material and Methods In this prospective, single‐centre follow‐up study, 175 women with symptomatic uterine fibroids were treated with MR‐HIFU. The effect of MR‐HIFU on fibroid symptoms and quality of life was evaluated using a uterine fibroid‐specific quality of life questionnaire (UFS‐QoL). The main outcome measure was the symptom severity score and quality of life (QoL) before the MR‐HIFU and 3 and 12 months after the treatment. This study was registered at clinicaltrials.gov (NCT03937401).
Results
The median symptom severity score decreased from 56 (IQR 44–69) at baseline to 28 (IQR 16–44) at 3 months ( p < 0.01) and 25 (IQR 16–38) at 12 months ( p < 0.01) after treatment. The QoL score increased from a median of 48 (IQR 33–66) at baseline to 73 (IQR 59–93) at 3 months ( p < 0.01) and 78 (IQR 66–90) at 12 months after treatment ( p < 0.01). The reintervention rate during the 12‐month follow‐up was 2%.
Conclusions
MR‐HIFU significantly reduces the severity of fibroid‐related symptoms in selected patients as early as 3 months after MR‐HIFU. The effect persists at 12 months. There is also a significant improvement in the quality of life 3 months after treatment, which further increases at 12 months.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Obstetrics and Gynaecology, Turku University Hospital, Turku, Finland.
- University of Turku, Turku, Finland.
- Department of Radiology, Turku University Hospital, Turku, Finland.
- Department of Medical Physics, Turku University Hospital, Turku, Finland.
ORCID profiles: Saara Otonkoski, Antti Perheentupa, Kirsi Joronen
Funding
- Finnish Government Research Funding
Cite
APA
Otonkoski, S., Viitala, A., Komar, G., Sainio, T., Yanovskiy, A., Blanco Sequieros, R., Perheentupa, A., & Joronen, K. (2025). Magnetic resonance guided high intensity focused ultrasound ( MR ‐ HIFU ) effectively reduces fibroid‐related symptoms and improves quality of life—A prospective single‐centre 12‐month follow‐up study. Acta Obstetricia et Gynecologica Scandinavica, 104(6), 1172-1180. https://doi.org/10.1111/aogs.15086
Vancouver
Otonkoski S, Viitala A, Komar G, Sainio T, Yanovskiy A, Blanco Sequieros R, et al. Magnetic resonance guided high intensity focused ultrasound ( MR ‐ HIFU ) effectively reduces fibroid‐related symptoms and improves quality of life—A prospective single‐centre 12‐month follow‐up study. Acta Obstetricia et Gynecologica Scandinavica. 2025;104(6):1172-1180. doi:10.1111/aogs.15086
BibTeX
@article{Otonkoski2025,
author = {Otonkoski, Saara and Viitala, Antti and Komar, Gaber and Sainio, Teija and Yanovskiy, Anna and Blanco Sequieros, Roberto and Perheentupa, Antti and Joronen, Kirsi},
title = {Magnetic resonance guided high intensity focused ultrasound ( MR ‐ HIFU ) effectively reduces fibroid‐related symptoms and improves quality of life—A prospective single‐centre 12‐month follow‐up study},
journal = {Acta Obstetricia et Gynecologica Scandinavica},
year = {2025},
volume = {104},
number = {6},
pages = {1172--1180},
doi = {10.1111/aogs.15086}
}
EUVIMED